Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of oral XH-5102 in myeloproliferative neoplasms
ChiCTR2300069803Phase 2Not yet recruiting
- Sponsor
- Shanghai Sixth People's Hospital
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of XH-5102 in myeloproliferative disorder (MPD), myelofibrosis (MF), polycythemia vera (PV) and 1 more, sponsored by Shanghai Sixth People's Hospital. Primary endpoints: Maximum tolerated dose and Safety. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
XH-5102
03
Conditions
myeloproliferative disorder (MPD)myelofibrosis (MF)polycythemia vera (PV)thrombocythemia
Beyond the preview
Go deeper on ChiCTR2300069803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069803.